Market Place
Sourcing Support
US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities
The pharmaceutical industry in the United States continued to
grapple with drug shortages during th
FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer blockbuster Tasigna lead 2024 patent cliff
A watershed moment in the journey of a drug is when it transitions from being a patented, high‐
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
